Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial.

Devereux G, Cotton S, Fielding S, McMeekin N, Barnes PJ, Briggs A, Burns G, Chaudhuri R, Chrystyn H, Davies L, De Soyza A, Gompertz S, Haughney J, Innes K, Kaniewska J, Lee A, Morice A, Norrie J, Sullivan A, Wilson A, Price D.

JAMA. 2018 Oct 16;320(15):1548-1559. doi: 10.1001/jama.2018.14432.

PMID:
30326124
2.

A qualitative synthesis of gastro-oesophageal reflux in bronchiectasis: Current understanding and future risk.

McDonnell MJ, O'Toole D, Ward C, Pearson JP, Lordan JL, De Soyza A, Loebinger M, Chalmers JD, Laffey JG, Rutherford RM.

Respir Med. 2018 Aug;141:132-143. doi: 10.1016/j.rmed.2018.06.031. Epub 2018 Jun 30. Review.

PMID:
30053958
3.

Genomic characterisation of an international Pseudomonas aeruginosa reference panel indicates that the two major groups draw upon distinct mobile gene pools.

Freschi L, Bertelli C, Jeukens J, Moore MP, Kukavica-Ibrulj I, Emond-Rheault JG, Hamel J, Fothergill JL, Tucker NP, McClean S, Klockgether J, de Soyza A, Brinkman FSL, Levesque RC, Winstanley C.

FEMS Microbiol Lett. 2018 Jul 1;365(14). doi: 10.1093/femsle/fny120.

PMID:
29897457
4.

Targeting the Bacterial Cytoskeleton of the Burkholderia cepacia Complex for Antimicrobial Development: A Cautionary Tale.

Carnell SC, Perry JD, Borthwick L, Vollmer D, Biboy J, Facchini M, Bragonzi A, Silipo A, Vergunst AC, Vollmer W, Khan ACM, De Soyza A.

Int J Mol Sci. 2018 May 30;19(6). pii: E1604. doi: 10.3390/ijms19061604.

5.

Anti-bacterial antibody and T cell responses in bronchiectasis are differentially associated with lung colonization and disease.

Jaat FG, Hasan SF, Perry A, Cookson S, Murali S, Perry JD, Lanyon CV, De Soyza A, Todryk SM.

Respir Res. 2018 May 30;19(1):106. doi: 10.1186/s12931-018-0811-2.

6.

Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: protocol of a randomised controlled proof-of-concept trial (APPLE COPD-ICON 2).

Kunadian V, Chan D, Ali H, Wilkinson N, Howe N, McColl E, Thornton J, von Wilamowitz-Moellendorff A, Holstein EM, Burns G, Fisher A, Stocken D, De Soyza A; APPLE COPD-ICON2 Trial Investigators.

BMJ Open. 2018 May 26;8(5):e020713. doi: 10.1136/bmjopen-2017-020713.

7.

Outcomes of lung transplantation in adults with bronchiectasis.

Birch J, Sunny SS, Hester KLM, Parry G, Kate Gould F, Dark JH, Clark SC, Meachery G, Lordan J, Fisher AJ, Corris PA, De Soyza A.

BMC Pulm Med. 2018 May 22;18(1):82. doi: 10.1186/s12890-018-0634-4.

8.

Patient information, education and self-management in bronchiectasis: facilitating improvements to optimise health outcomes.

Hester KLM, Newton J, Rapley T, De Soyza A.

BMC Pulm Med. 2018 May 22;18(1):80. doi: 10.1186/s12890-018-0633-5. Review.

9.

Quantifying patient centered outcomes associated with the use of bilateral endobronchial coil treatment in patients with severe emphysema.

Evans R, Brutsche M, Busca R, Deslee G, de Soyza A, Fellrath JM, Franzen D, Hartman J, Mealing S, Morton T, Munavvar M, Sculpher M, Shah P, Slebos DJ, Durand-Zaleski I.

Curr Med Res Opin. 2018 Nov;34(11):1927-1932. doi: 10.1080/03007995.2018.1462784. Epub 2018 May 8.

PMID:
29625529
10.

Information and education provision in bronchiectasis: co-development and evaluation of a novel patient-driven resource in a digital era.

Hester KLM, Newton J, Rapley T, Ryan V, De Soyza A.

Eur Respir J. 2018 Apr 12;51(4). pii: 1702402. doi: 10.1183/13993003.02402-2017. Print 2018 Apr. No abstract available.

PMID:
29496753
11.

The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis.

Araújo D, Shteinberg M, Aliberti S, Goeminne PC, Hill AT, Fardon TC, Obradovic D, Stone G, Trautmann M, Davis A, Dimakou K, Polverino E, De Soyza A, McDonnell MJ, Chalmers JD.

Eur Respir J. 2018 Jan 31;51(2). pii: 1701953. doi: 10.1183/13993003.01953-2017. Print 2018 Feb.

PMID:
29386336
12.

RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.

Aksamit T, De Soyza A, Bandel TJ, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R.

Eur Respir J. 2018 Jan 25;51(1). pii: 1702053. doi: 10.1183/13993003.02053-2017. Print 2018 Jan.

PMID:
29371384
13.

RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.

De Soyza A, Aksamit T, Bandel TJ, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R.

Eur Respir J. 2018 Jan 25;51(1). pii: 1702052. doi: 10.1183/13993003.02052-2017. Print 2018 Jan.

PMID:
29371383
14.

Characterization of the "Frequent Exacerbator Phenotype" in Bronchiectasis.

Chalmers JD, Aliberti S, Filonenko A, Shteinberg M, Goeminne PC, Hill AT, Fardon TC, Obradovic D, Gerlinger C, Sotgiu G, Operschall E, Rutherford RM, Dimakou K, Polverino E, De Soyza A, McDonnell MJ.

Am J Respir Crit Care Med. 2018 Jun 1;197(11):1410-1420. doi: 10.1164/rccm.201711-2202OC.

PMID:
29357265
15.

Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network.

Chalmers JD, Ringshausen FC, Harris B, Elborn JS, Posthumus A, Haworth CS, Pilkington N, Polverino E, Ruddy T, Aliberti S, Goeminne PC, Winstanley C, De Soyza A.

Eur Respir J. 2018 Jan 11;51(1). pii: 1701937. doi: 10.1183/13993003.01937-2017. Print 2018 Jan. No abstract available.

PMID:
29326319
16.

Standardised classification of the aetiology of bronchiectasis using an objective algorithm.

Araújo D, Shteinberg M, Aliberti S, Goeminne PC, Hill AT, Fardon T, Obradovic D, Dimakou K, Polverino E, De Soyza A, McDonnell MJ, Chalmers JD.

Eur Respir J. 2017 Dec 14;50(6). pii: 1701289. doi: 10.1183/13993003.01289-2017. Print 2017 Dec. No abstract available.

PMID:
29242262
17.

The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration.

Chalmers JD, Crichton M, Goeminne PC, Loebinger MR, Haworth C, Almagro M, Vendrell M, De Soyza A, Dhar R, Morgan L, Blasi F, Aliberti S, Boyd J, Polverino E.

Breathe (Sheff). 2017 Sep;13(3):180-192. doi: 10.1183/20734735.005117. Review.

18.

European Respiratory Society guidelines for the management of adult bronchiectasis.

Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Cantón R, Torres A, Dimakou K, De Soyza A, Hill AT, Haworth CS, Vendrell M, Ringshausen FC, Subotic D, Wilson R, Vilaró J, Stallberg B, Welte T, Rohde G, Blasi F, Elborn S, Almagro M, Timothy A, Ruddy T, Tonia T, Rigau D, Chalmers JD.

Eur Respir J. 2017 Sep 9;50(3). pii: 1700629. doi: 10.1183/13993003.00629-2017. Print 2017 Sep.

PMID:
28889110
19.

Heightened autoantibody immune response to citrullinated calreticulin in bronchiectasis: Implications for rheumatoid arthritis.

Clarke A, Perry E, Kelly C, De Soyza A, Heesom K, Gold LI, Ollier W, Hutchinson D, Eggleton P.

Int J Biochem Cell Biol. 2017 Aug;89:199-206. doi: 10.1016/j.biocel.2017.06.013. Epub 2017 Jun 24.

PMID:
28652209
20.

Cough and bronchiectasis.

McCallion P, De Soyza A.

Pulm Pharmacol Ther. 2017 Dec;47:77-83. doi: 10.1016/j.pupt.2017.04.010. Epub 2017 Jun 7. Review.

PMID:
28602999
21.

Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research.

Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, Chalmers JD, De Soyza A, Dimakou K, Elborn JS, Feldman C, Flume P, Goeminne PC, Loebinger MR, Menendez R, Morgan L, Murris M, Polverino E, Quittner A, Ringshausen FC, Tino G, Torres A, Vendrell M, Welte T, Wilson R, Wong C, O'Donnell A, Aksamit T; EMBARC/BRR definitions working group.

Eur Respir J. 2017 Jun 8;49(6). pii: 1700051. doi: 10.1183/13993003.00051-2017. Print 2017 Jun.

PMID:
28596426
22.

The heterogeneity of systemic inflammation in bronchiectasis.

Saleh AD, Chalmers JD, De Soyza A, Fardon TC, Koustas SO, Scott J, Simpson AJ, Brown JS, Hurst JR.

Respir Med. 2017 Jun;127:33-39. doi: 10.1016/j.rmed.2017.04.009. Epub 2017 Apr 17.

PMID:
28502416
23.

The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis.

Aksamit T, Bandel TJ, Criollo M, De Soyza A, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R.

Contemp Clin Trials. 2017 Jul;58:78-85. doi: 10.1016/j.cct.2017.05.007. Epub 2017 May 8.

24.

Pseudomonas aeruginosa adaptation and diversification in the non-cystic fibrosis bronchiectasis lung.

Hilliam Y, Moore MP, Lamont IL, Bilton D, Haworth CS, Foweraker J, Walshaw MJ, Williams D, Fothergill JL, De Soyza A, Winstanley C.

Eur Respir J. 2017 Apr 26;49(4). pii: 1602108. doi: 10.1183/13993003.02108-2016. Print 2017 Apr.

25.

The Use of Plasmapheresis in Patients with Bronchiectasis with Pseudomonas aeruginosa Infection and Inhibitory Antibodies.

Wells TJ, Davison J, Sheehan E, Kanagasundaram S, Spickett G, MacLennan CA, Stockley RA, Cunningham AF, Henderson IR, De Soyza A.

Am J Respir Crit Care Med. 2017 Apr 1;195(7):955-958. doi: 10.1164/rccm.201603-0599LE. No abstract available.

PMID:
28362198
26.

Psychological therapies for the treatment of anxiety disorders in chronic obstructive pulmonary disease.

Usmani ZA, Carson KV, Heslop K, Esterman AJ, De Soyza A, Smith BJ.

Cochrane Database Syst Rev. 2017 Mar 21;3:CD010673. doi: 10.1002/14651858.CD010673.pub2. Review.

PMID:
28322440
27.

Bronchiectasis Rheumatoid Overlap Syndrome Is an Independent Risk Factor for Mortality in Patients With Bronchiectasis: A Multicenter Cohort Study.

De Soyza A, McDonnell MJ, Goeminne PC, Aliberti S, Lonni S, Davison J, Dupont LJ, Fardon TC, Rutherford RM, Hill AT, Chalmers JD.

Chest. 2017 Jun;151(6):1247-1254. doi: 10.1016/j.chest.2016.12.024. Epub 2017 Jan 16.

28.

Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study.

McDonnell MJ, Aliberti S, Goeminne PC, Restrepo MI, Finch S, Pesci A, Dupont LJ, Fardon TC, Wilson R, Loebinger MR, Skrbic D, Obradovic D, De Soyza A, Ward C, Laffey JG, Rutherford RM, Chalmers JD.

Lancet Respir Med. 2016 Dec;4(12):969-979. doi: 10.1016/S2213-2600(16)30320-4. Epub 2016 Nov 16.

29.

Bronchiectasis and Aspergillus: How are they linked?

De Soyza A, Aliberti S.

Med Mycol. 2017 Jan 1;55(1):69-81. Epub 2016 Oct 28. Review.

PMID:
27794529
30.

The EMBARC European Bronchiectasis Registry: protocol for an international observational study.

Chalmers JD, Aliberti S, Polverino E, Vendrell M, Crichton M, Loebinger M, Dimakou K, Clifton I, van der Eerden M, Rohde G, Murris-Espin M, Masefield S, Gerada E, Shteinberg M, Ringshausen F, Haworth C, Boersma W, Rademacher J, Hill AT, Aksamit T, O'Donnell A, Morgan L, Milenkovic B, Tramma L, Neves J, Menendez R, Paggiaro P, Botnaru V, Skrgat S, Wilson R, Goeminne P, De Soyza A, Welte T, Torres A, Elborn JS, Blasi F.

ERJ Open Res. 2016 Jan 20;2(1). pii: 00081-2015. eCollection 2016 Jan.

31.

Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts.

McDonnell MJ, Aliberti S, Goeminne PC, Dimakou K, Zucchetti SC, Davidson J, Ward C, Laffey JG, Finch S, Pesci A, Dupont LJ, Fardon TC, Skrbic D, Obradovic D, Cowman S, Loebinger MR, Rutherford RM, De Soyza A, Chalmers JD.

Thorax. 2016 Dec;71(12):1110-1118. doi: 10.1136/thoraxjnl-2016-208481. Epub 2016 Aug 11.

32.

Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis.

Wilson R, Aksamit T, Aliberti S, De Soyza A, Elborn JS, Goeminne P, Hill AT, Menendez R, Polverino E.

Respir Med. 2016 Aug;117:179-89. doi: 10.1016/j.rmed.2016.06.007. Epub 2016 Jun 7. Review.

33.

Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration.

Aliberti S, Masefield S, Polverino E, De Soyza A, Loebinger MR, Menendez R, Ringshausen FC, Vendrell M, Powell P, Chalmers JD; EMBARC Study Group.

Eur Respir J. 2016 Sep;48(3):632-47. doi: 10.1183/13993003.01888-2015. Epub 2016 Jun 10.

34.

Evaluation of a novel information resource for patients with bronchiectasis: study protocol for a randomised controlled trial.

Hester KL, Newton J, Rapley T, De Soyza A.

Trials. 2016 Apr 23;17(1):210. doi: 10.1186/s13063-016-1330-4.

35.

Telomere Dysfunction and Senescence-associated Pathways in Bronchiectasis.

Birch J, Victorelli S, Rahmatika D, Anderson RK, Jiwa K, Moisey E, Ward C, Fisher AJ, De Soyza A, Passos JF.

Am J Respir Crit Care Med. 2016 Apr 15;193(8):929-32. doi: 10.1164/rccm.201510-2035LE. No abstract available.

36.

The generalizability of bronchiectasis randomized controlled trials: A multicentre cohort study.

Chalmers JD, McDonnell MJ, Rutherford R, Davidson J, Finch S, Crichton M, Dupont L, Hill AT, Fardon TC, De Soyza A, Aliberti S, Goeminne P.

Respir Med. 2016 Mar;112:51-8. doi: 10.1016/j.rmed.2016.01.016. Epub 2016 Jan 29.

37.

Bronchiectasis: how to be an orphan with many parents?

Goeminne PC, De Soyza A.

Eur Respir J. 2016 Jan;47(1):10-3. doi: 10.1183/13993003.01567-2015. No abstract available.

38.

Critical care admission trends and outcomes in individuals with bronchiectasis in the UK.

Navaratnam V, Muirhead CR, Hubbard RB, De Soyza A.

QJM. 2016 Aug;109(8):523-6. doi: 10.1093/qjmed/hcv206. Epub 2015 Nov 17.

39.

Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity.

Lonni S, Chalmers JD, Goeminne PC, McDonnell MJ, Dimakou K, De Soyza A, Polverino E, Van de Kerkhove C, Rutherford R, Davison J, Rosales E, Pesci A, Restrepo MI, Torres A, Aliberti S.

Ann Am Thorac Soc. 2015 Dec;12(12):1764-70. doi: 10.1513/AnnalsATS.201507-472OC.

40.

DNA damage response at telomeres contributes to lung aging and chronic obstructive pulmonary disease.

Birch J, Anderson RK, Correia-Melo C, Jurk D, Hewitt G, Marques FM, Green NJ, Moisey E, Birrell MA, Belvisi MG, Black F, Taylor JJ, Fisher AJ, De Soyza A, Passos JF.

Am J Physiol Lung Cell Mol Physiol. 2015 Nov 15;309(10):L1124-37. doi: 10.1152/ajplung.00293.2015. Epub 2015 Sep 18.

41.

A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis.

De Soyza A, Pavord I, Elborn JS, Smith D, Wray H, Puu M, Larsson B, Stockley R.

Eur Respir J. 2015 Oct;46(4):1021-32. doi: 10.1183/13993003.00148-2015. Epub 2015 Sep 4.

42.

Phenotypic characterization of an international Pseudomonas aeruginosa reference panel: strains of cystic fibrosis (CF) origin show less in vivo virulence than non-CF strains.

Cullen L, Weiser R, Olszak T, Maldonado RF, Moreira AS, Slachmuylders L, Brackman G, Paunova-Krasteva TS, Zarnowiec P, Czerwonka G, Reilly J, Drevinek P, Kaca W, Melter O, De Soyza A, Perry A, Winstanley C, Stoitsova SR, Lavigne R, Mahenthiralingam E, Sá-Correia I, Coenye T, Drulis-Kawa Z, Augustyniak D, Valvano MA, McClean S.

Microbiology. 2015 Oct;161(10):1961-77. doi: 10.1099/mic.0.000155. Epub 2015 Aug 6.

PMID:
26253522
43.

Increased disease activity, severity and autoantibody positivity in rheumatoid arthritis patients with co-existent bronchiectasis.

Perry E, Eggleton P, De Soyza A, Hutchinson D, Kelly C.

Int J Rheum Dis. 2017 Dec;20(12):2003-2011. doi: 10.1111/1756-185X.12702. Epub 2015 Jul 22.

PMID:
26200759
44.

Activation of Human Toll-like Receptor 4 (TLR4)·Myeloid Differentiation Factor 2 (MD-2) by Hypoacylated Lipopolysaccharide from a Clinical Isolate of Burkholderia cenocepacia.

Di Lorenzo F, Kubik Ł, Oblak A, Lorè NI, Cigana C, Lanzetta R, Parrilli M, Hamad MA, De Soyza A, Silipo A, Jerala R, Bragonzi A, Valvano MA, Martín-Santamaría S, Molinaro A.

J Biol Chem. 2015 Aug 28;290(35):21305-19. doi: 10.1074/jbc.M115.649087. Epub 2015 Jul 9.

45.

Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.

Devereux G, Cotton S, Barnes P, Briggs A, Burns G, Chaudhuri R, Chrystyn H, Davies L, De Soyza A, Fielding S, Gompertz S, Haughney J, Lee AJ, McCormack K, McPherson G, Morice A, Norrie J, Sullivan A, Wilson A, Price D.

Trials. 2015 Jun 10;16:267. doi: 10.1186/s13063-015-0782-2.

46.

Bronchiectasis is a Model for Chronic Bacterial Infection Inducing Autoimmunity in Rheumatoid Arthritis.

Quirke AM, Perry E, Cartwright A, Kelly C, De Soyza A, Eggleton P, Hutchinson D, Venables PJ.

Arthritis Rheumatol. 2015 Sep;67(9):2335-42. doi: 10.1002/art.39226.

47.

Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD: a randomised, cross-over, multicentre study.

Pascual S, Feimer J, De Soyza A, Sauleda Roig J, Haughney J, Padullés L, Seoane B, Rekeda L, Ribera A, Chrystyn H.

NPJ Prim Care Respir Med. 2015 Apr 30;25:15018. doi: 10.1038/npjpcrm.2015.18.

48.

Quality compared to quantity of life in laryngeal cancer: A time trade-off study.

Hamilton DW, Bins JE, McMeekin P, Pedersen A, Steen N, De Soyza A, Thomson R, Paleri V, Wilson JA.

Head Neck. 2016 Apr;38 Suppl 1:E631-7. doi: 10.1002/hed.24061. Epub 2015 Jun 15.

PMID:
25832305
49.

Large trials, new knowledge: the changing face of COPD management.

De Soyza A, Calverley PM.

Eur Respir J. 2015 Jun;45(6):1692-703. doi: 10.1183/09031936.00179714. Epub 2015 Mar 18. Review.

50.

In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients.

Olszak T, Zarnowiec P, Kaca W, Danis-Wlodarczyk K, Augustyniak D, Drevinek P, de Soyza A, McClean S, Drulis-Kawa Z.

Appl Microbiol Biotechnol. 2015 Jul;99(14):6021-33. doi: 10.1007/s00253-015-6492-6. Epub 2015 Mar 12.

Supplemental Content

Loading ...
Support Center